These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial. Fisher M; Gore M Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284 [TBL] [Abstract][Full Text] [Related]
11. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Sehouli J; Alfaro V; González-Martín A Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421 [TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent ovarian cancer. Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464 [TBL] [Abstract][Full Text] [Related]
16. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. Colombo N Future Oncol; 2017 Oct; 13(23s):23-29. PubMed ID: 29020821 [TBL] [Abstract][Full Text] [Related]
17. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer. Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956 [TBL] [Abstract][Full Text] [Related]
18. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933 [TBL] [Abstract][Full Text] [Related]